All Clinical Trials in United Kingdom

A listing of 3097 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

United Kingdom

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

A Phase 1b Trial to Evaluate Safety of MB097 in Combination with Pembrolizumab in Melanoma Patients

NCT06540391

Recruiting

A Phase 1b study to evaluate the safety and tolerability of MB097 given in combination with pembrolizumab in patients with melanoma who demonstrate primary resistance to anti-PD1 therapy.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/04/2025

Locations: Centre Georges Francois Leclerc, Dijon, Not set +18 locations

Conditions: Melanoma

Learn More ›

Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis

NCT04562389

Recruiting

This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended Phase 2 dose (RP2D) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a)... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/03/2025

Locations: UAB Division of Hematology/Oncology, Birmingham, Alabama +148 locations

UAB Division of Hematology/Oncology, Birmingham, Alabama

UCLA - Satellite Site, Beverly Hills, California

City of Hope, Duarte, California

UCLA - Satellite Site, Encino, California

City of Hope - Irvine Lennar - Satellite, Irvine, California

UCLA, Los Angles, California

The Oncology Institute of Hope & Innovation, Pasadena, California

USOR - Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado

Smilow Cancer Hospital - New Haven, New Haven, Connecticut

Norton Cancer Institute - Saint Matthews, Louisville, Kentucky

Maryland Oncology Hematology-Satellite, Annapolis, Maryland

The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Maryland Oncology Hematology-Satellite, Brandywine, Maryland

Maryland Oncology Hematology, Columbia, Maryland

Maryland Oncology Hematology-Satellite, Rockville, Maryland

Maryland Oncology Hematology-Satellite, Silver Spring, Maryland

The Cancer & Hematology Centers -Satellite Site, Grand Rapids, Michigan

The Cancer & Hematology Centers of Muskegon, Norton Shores, Michigan

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey

Mount Sinai Health System, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

Duke Cancer Institue, Durham, North Carolina

USOR - Oncology Hematology Care - Kenwood, Cincinnati, Ohio

OhioHealth, Columbus, Ohio

Vanderbilt Ingram Cancer Center, Nashville, Tennessee

Texas Oncology, Dallas, Texas

University of Texas MD Anderson Cancer Center, Houston, Texas

Huntsman Cancer Institute, Salt Lake City, Utah

USOR - Virginia Cancer Specialists - Gainesville Office, Gainesville, Virginia

VCU Massey Cancer Center, Richmond, Virginia

USOR - Virginia Oncology Associates - Virginia Beach, Virginia Beach, Virginia

Fred Hutchinson Cancer Center - SCAA South Lake Union, Seattle, Washington

West Virginia University Cancer Institute, Wheeling Hospital, Wheeling, West Virginia

University of Wisconsin - Madison, Madison, Wisconsin

Universitair Ziekenhuis Leuven - Campus Gasthuisberg, Leuven, Flemish Brabant

Universitair Ziekenhuis Gent, Gent, Oost-Vlaanderen

Algemeen Ziekenhuis Sint-Jan Brugge-Oostende - Campus Sint-Jan, Brugge, West-Vlaanderen

ZNA Stuivenberg - Satelite, Antwerpen, Not set

ZNA Stuivenberg, Antwerpen, Not set

University Multiprofile Hospital for Active Treatment Sveti George - Base 1, Plovdiv, Not set

University Multiprofile Hospital for Active Treatment Aleksandrovska, Sofia, Not set

University Multiprofile Hospital for Active Treatment St. Ivan Rilski, Sofia, Not set

Specialized Hospital for Active Treatment of Hematological Diseases - EAD Sofia, Sofia, Not set

University Multiprofile Hospital for Active Treatment - Prof. Dr. Stoyan Kirkovich, Stara Zagora, Not set

University of Alberta Hospital, Edmonton, Alberta

Research Institute of the McGill University Health Centre, Montreal, Quebec

Vseobecna Fakultni Nemocnice v Praze, Praha 2, Prague

Fakultní Nemocnice Hradec Králové, Hradec Králové, Not set

Fakultní Nemocnice Olomouc, Olomouc, Not set

Aarhus Universitetshospital, Aarhus N, Midtjylland

Tang Severinsen, Marianne, Aalborg, Nordjylland

Institut Bergonié, Bordeaux, Aquitaine

Centre Hospitalier Universitaire Estaing, Clermont-Ferrand, Aubergne

Hôpital Morvan, Brest, Bretagne

Chu De Nîmes - Institut De Cancérologie Du Gard, Nimes, Gard

Hôpital Emile Muller, Mulhouse, Grand Est

Hôpital Huriez, Lille, Hauts-de-France

Hôpital Universitaire Pitié Salpêtrière, Paris, Ile-de-France

Hôpital Bretonneau, Tours Cedex, Indre-et-Loire

Centre Hospitalier Universitaire de Saint-Étienne, Saint-Priest-en-Jarez, Loire

Hôpital l'Archet - CHU Nice, Nice Cedex 3, Paca

Centre Hospitalier Universitaire d'Angers, Angers, Pays de la Loire

Centre Hospitalier Lyon-Sud, Pierre-Bénite, Rhone-Alpes

Hôpital Saint-Louis, Paris, Not set

Kliniken Ostalb - Stauferklinikum Schwäbisch Gmünd, Mutlangen, Baden-Württemberg

Marien Hospital Düsseldorf, Düsseldorf, Nordrhein-Westfalen

Universitätsklinikum Halle, Halle, Sachsen-Anhalt

Städtisches Krankenhaus Kiel, Kiel, Schleswig-Holstein

Universitätsklinikum Jena, Jena, Thuringen

Laiko General Hospital of Athens, Athens, Attica

University General Hospital Attikon, Athens, Attica

General Hospital of Thessaloniki George Papanikolaou, Thessaloniki, Central Macedonia

University General Hospital of Larissa, Hematology Department, Larissa, Thessaly

Győr-Moson-Sopron Vármegyei Petz Aladár Egyetemi Oktató Kórház, Győr, Gyor-Moson-Sopron

Semmelweis Egyetem, Budapest, Not set

Shamir Medical Center (Assaf Harofeh), Be'er Ya'akov, Central District

The Chaim Sheba Medical Center, Ramat Gan, Central District

Rambam Health Care Campus, Haifa, Haifa District

Carmel Medical Center, Haifa, Haifa District

Hadassah University Hospital - Mount Scopus - Satellite Site, Jerusalem, Jerusalem District

Hadassah University Hospital Ein Kerem, Jerusalem, Jerusalem District

Emek Medical Center, Afula, Northern District

Western Galilee Hospital-Nahariya, Nahariya, Northern District

Tel Aviv Sourasky Medical Center, Tel Aviv, Not set

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST, Meldola, Forli-Cesena

IRCCS Ospedale Policlinico San Martino, Genova, Genoa

Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico, Milano, Milan

Istituto Europeo di Oncologia, Milano, Milan

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milano, Milan

Fondazione IRCCS San Gerardo dei Tintori, Monza, Monza and Brianza

IRCCS Centro di Riferimento Oncologico di Basilicata, Rionero In Vulture, Potenza

Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino, Turin

Università Campus Bio-Medico di Roma, Rome, Viterbo

Azienda Ospedaliero-Universitaria di Bologna - Policlinico Sant Orsola-Malpighi, Bologna, Not set

Azienda Ospedaliero - Universitaria Careggi, Firenze, Not set

Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara, Novara, Not set

Fondazione IRCCS Policlinico San Matteo, Pavia, Not set

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Not set

Azienda Ospedaliera Ordine Mauriziano di Torino, Torino, Not set

Centro Ricerche Cliniche di Verona, Verona, Not set

Pusan National University Hospital, Busan Gwang'yeogsi [Pusan-Kwangyokshi], Not set

Kyungpook National University Hospital, Daegu, Not set

Chonnam National University Hwasun Hospital, Hwasun-gun, Not set

Seoul National University Bundang Hospital, Seongnam-si Gyeonggido [Kyonggi-do], Not set

Samsung Medical Center, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital, Seoul, Not set

The Catholic University of Korea - Seoul St. Mary's Hospital, Seoul, Not set

Universitair Medisch Centrum Groningen, Groningen, Not set

Dolnośląskie Centrum Transplantacji Komórkowych z Krajowym Bankiem Dawców Szpiku, Wrocław, Dolnoslaskie

Medicover Integrated Clinical Services (MICS) - Centrum Medyczne Toruń, Toruń, Kujawsko-Pomorskie

Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie, Lublin, Lubelskie

Szpital Specjalistyczny w Brzozowie - Podkarpacki Ośrodek Onkologiczny im. Ks. B. Markiewicza, Brzozów, Podkarpackie

Uniwersyteckie Centrum Kliniczne w Gdańsku, Gdańsk, Pomorskie

Pratia Onkologia Katowice, Katowice, Slaskie

Specjalistyczny Szpital im. dra Alfreda Sokołowskiego w Wałbrzychu, Wałbrzych, Slaskie

AIDPORT, Skórzewo, Wielkopolskie

Institutul Oncologic Prof. Dr. Ion Chiricuta, Cluj-Napoca, Cluj

Spitalul Filantropia - Craiova, Craiova, Dolj

Institutul Regional De Oncologie Iasi, Moldova, Iasi

Spitalul Clinic Judetean De Urgenta Târgu Mureș, Târgu Mureş, Mureș

Coltea - Spital Clinic, Bucuresti, Not set

Spitalul Clinic Colentina, Bucuresti, Not set

Hospital Universitario Central de Asturias, Oviedo, Asturias

Institut Català d'Oncologia Badalona, Badalona, Not set

Hospital Universitari Vall d'Hebrón, Barcelona, Not set

Hospital Clinic de Barcelona, Barcelona, Not set

Institut Català d'Oncologia Girona (ICO Girona), Girona, Not set

Hospital Universitario de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Not set

Hospital Universitario Lucus Augusti, Lugo, Not set

Hospital General Universitario Gregorio Marañón, Madrid, Not set

Hospital Universitario Ramón y Cajal, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Not set

Hospital Universitario Virgen de la Victoria, Málaga, Not set

Complejo Asistencial Universitario de Salamanca - Hospital Clínico, Salamanca, Not set

Hospital Clínico Universitario de Valencia, Valencia, Not set

China Medical University Hospital, Taichung City, Taichung

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Not set

Chang Gung Memorial Hospital - Kaohsiung Branch, Kaohsiung, Not set

National Taiwan University Hospital, Taipei City, Not set

Chang Gung Memorial Hospital - Linkou Branch, Taoyuan, Not set

Guy's and St Thomas' NHS Foundation Trust, London, England

Oxford University Hospitals NHS Foundation Trust, Oxford, England

United Lincolnshire Hospitals NHS Trust-Satellite Site, Boston, Not set

United Lincolnshire Hospitals NHS Trust, Boston, Not set

The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, Not set

Imperial College Healthcare NHS Trust, London, Not set

The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, Not set

Conditions: Myelofibrosis

Learn More ›

Exploring the Lived Experience of Young Adults With Severe Asthma

NCT06681545

Recruiting

Asthma is a serious long-term lung condition caused by swollen airways that narrow. This causes wheezing, chest tightness, and breathlessness. Most asthma is well-controlled with medication. However, 5-10% of asthmatics have severe asthma where treatment does not control symptoms and up to 67% of asthmatics have uncontrolled asthma, caused by not always taking medication as recommended, lifestyle choices or other health problems worsening their asthma. In the UK, asthma affects around 800,000 young adults. This group is at high-risk of having poor asthma control, worse outcomes than other age-groups. This is because young adults need care that differs from other age-groups and current care is not meeting these needs. There is little information on the experiences and needs of this group and very few studies exist, exploring how to improve care. This study will explore the experiences and needs of young adults (age16-25) with severe and uncontrolled asthma. Methods. The investigators will perform two study-arms with young adults with severe/uncontrolled asthma in Manchester and Liverpool severe asthma centres: Study-arm 1: Interview participants using photographs chosen by them to help explain their experiences of living with asthma and support that they need. Study arm 2: Perform group interviews to understand participants' thoughts around the insights from study-arm 1 combined with their own experiences. To explore and develop ideas on how to improve future care. At the end of both study arms, a workshop involving patients and stakeholders involved in delivering care will take place, to identify a joint goal of how to improve care in this cohort and map ways in which to achieve this. Together, the study results and workshop will increase our understanding of the experiences and needs of young adults with asthma. Helping us to identify new ways to improve care which can be tested in future research. Read Less

Gender:

ALL

Ages:

Between 16 years and 25 years

Trial Updated:

02/03/2025

Locations: Severe asthma services based at both Manchester University Foundation NHS trust and Liverpool University Foundation NHS Trust, Manchester, Greater

Conditions: Asthma, Severe Asthma, Uncontrolled Asthma

Learn More ›

Post Approval Study to Evaluate the Safety and Performance of GENTA-FOIL Resorb® in Hand Surgery

NCT04482140

Recruiting

Single arm study to evaluate the safety and performance of Genta-Foil resorb® for the prevention of tissue adhesions

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/03/2025

Locations: KAT Attica General Hospital, Athens, Not set +2 locations

Conditions: Tissue Adhesions, Surgery-Induced

Learn More ›

BI-1808 As a Single Agent and with Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

NCT04752826

Recruiting

The goal of this first in human clinical trial is to test BI-1808 administered as single agent and in combination with pembrolizumab in subjects with advanced malignancies whose disease has progressed after standard therapy. The main questions it aims to answer are: * how safe and tolerable is BI-1808 * what is maximum tolerated or administrated dose * to determine recommended dose for further clinical trials. Participants will receive infusions of BI-1808 alone or combination with pembrolizum... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/03/2025

Locations: City of Hope National Medical Center, Duarte, California +18 locations

Conditions: Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma, Melanoma

Learn More ›

Primary Care Management of Osteoporosis in Older Women

NCT06431867

Recruiting

The Investigators aim to improve primary-care for older women with osteoporosis. Older women they spoke with previously felt unseen, unimportant, unheard and uninformed. These women felt that bone/joint health was an important issue for women aged 70+. Osteoporosis is a disease that makes bones more breakable and can lead to significant pain, disability and death, costing approximately £4.4 billion a year in the United Kingdom. Women are four times more likely to have osteoporosis than men and suffer fractures earlier. Osteoporosis care is poor in primary care even though good guidelines are available. The Investigators will work with older women and healthcare professionals to help guide the research. They have already looked at published research and will build on this. They will identify what is important for both older women and professionals to inform the first interview questions. The Investigators will ask older women and healthcare professionals about the diagnosis and treatment of osteoporosis. They will also ask them how they manage osteoporosis as a patient or care provider. At regular intervals, the Investigators will look at the interview findings first and then share their thoughts with older women and professionals. Together they will explore what the interviews mean. These discussions may change the questions asked and who is interviewed next. The Investigators will combine all the information from interviews to identify what works well and less well in osteoporosis care. They will check these findings against the guidelines. They will continue to work with older women and healthcare professionals to develop recommendations for improving care. The Investigators will also identify areas of further work. They will share recommendations with healthcare commissioners and produce a summary for a variety of professional networks. They will also publish papers in journals aimed at healthcare professionals and produce a summary document and advice for older women to use. Read Less

Gender:

ALL

Ages:

70 years and above

Trial Updated:

02/03/2025

Locations: Bradford Institute for Health Research, Bradford, West Yorkshire

Conditions: Osteoporosis

Learn More ›

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

NCT05074810

Recruiting

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/03/2025

Locations: Rocky Mountain Cancer Center, LLP, Boulder, Colorado +33 locations

Rocky Mountain Cancer Center, LLP, Boulder, Colorado

Georgetown University Medical Center, Washington, District of Columbia

MedStar Washington Hospital Center, MedStar Georgetown Cancer Institute,, Washington, District of Columbia

Illinois Cancer Specialists, Arlington Heights, Illinois

Maryland Oncology & Hematology, P.A., Rockville, Maryland

Dana Farber Cancer Institute, Boston, Massachusetts

Henry Ford Health System, Detroit, Michigan

Minnesota Oncology Hematology, P.A, Woodbury, Minnesota

Washington University School of Medicine, Saint Louis, Missouri

Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio

Ohio State University Brain and Spine Hospital, Columbus, Ohio

Consultants in Medical Oncology & Hematology, Broomall, Pennsylvania

Alliance Cancer Specialists,, Horsham, Pennsylvania

Texas Oncology, Austin, Texas

University of Texas Southwestern Medical Center, Dallas, Texas

Texas Oncology - Fort Worth Cancer Center, Fort Worth, Texas

Texas Oncology, Longview, Texas

Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Blacksburg, Virginia

Virginia Cancer Specialists, PC, Fairfax, Virginia

University Hospital Gent, Gent, Not set

CHU de Liège, Liège, Not set

CHRU of Lille, Lille, Not set

Hôpital Cochin, Paris, Not set

Hôpital Foch, Suresnes, Not set

Leids Universitair Medisch Centrum, Leiden, Not set

Erasmus MC, Rotterdam, Not set

Hospital Teresa Herrera (C.H.U.A.C), A Coruña, Not set

Hospital General Universitario Gregorio Marañón, Madrid, Not set

Hospital Universitario Fundación Jiménez Díaz, Madrid, Not set

Hospital Universitario Virgen De La Victoria, Málaga, Not set

Hospital Universitario Virgen de la Macarena, Sevilla, Not set

University of Leicester, Leicester, Not set

Royal Marsden Hospital, London, Not set

Royal Marsden Hospital, Sutton, Not set

Conditions: Non Small Cell Lung Cancer, KRAS Activating Mutation

Learn More ›

Biological Matrices Versus Synthetic Meshes

NCT05449691

Recruiting

In this feasibility study, 60 women undergoing reconstruction will be randomly allocated to receive biological or synthetic mesh and followed for 6 months. The findings will tell us if patients and surgeons are comfortable with not being able to choose which mesh is used for the operation. In the larger surgical study, the investigators plan to measure patients' satisfaction with the reconstruction, patients' quality of life, complications from the operation and costs over 5 years.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

02/03/2025

Locations: University Hospitals of Derby and Burton NHS Foundation Trust, Derby, Not set +4 locations

Conditions: Breast Cancer

Learn More ›

Lumeneye Rectoscope for Assessment on Tumor Response After Total Neoadjuvant Treatment in Rectal Cancer

NCT06189846

Recruiting

The objective of this prospective international cohort is to evaluate the LUMENEYE rectoscope for assessment on tumor response after total neoadjuvant treatment in rectal cancer. Patients included in this study will be patients who initially will be good candidates for organ preservation. The participating centers are all expert centers in tumor assessment. All patient assessments after neoadjuvant treatment for rectal adenocarcinoma will be included in each centre.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/03/2025

Locations: Clinique Tivoli-Ducos - Bordeaux Colorectal Institute, Bordeaux, Not set +7 locations

Conditions: Rectal Cancer

Learn More ›

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

NCT04557449

Recruiting

This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and then in combination with endocrine therapy. The study consists of two parts and a China and Japan monotherapy cohort. Part 1 includes dose escalation cohorts evaluating PF-07220060 as single agent or in combination with endocrine therapy or enzalutamide, as well as a food effect cohort and a DDI cohort Part 2 includes dose expansion cohorts evaluating PF-07220060 in combination with endocrine therapy or enzalutamide. In Part 1A, single escalating doses of PF-07220060 alone will be administered to determine the maximum tolerated dose (MTD) and select the recommended dose for expansion In Part 1B and Part 1C, PF-07220060 will be administered in combination with 1 of 2 endocrine therapies (letrozole and fulvestrant, respectively). In Part 1D, food effect assessment of PF-07220060 at the RP2D dose level from the Part 1A will be conducted In Part 1E, the effect of PF-07220060 on the PK of midazolam will be evaluated (DDI) In Part 1F, escalating dosed of PF-07220060 will be administered in combination with enzalutamide Part 1B and Part 1C may commence at MTD or before reaching the MTD at a dose level in Part 1A. Part 2A is a dose expansion cohort with fulvestrant and will explore more than one dose of PF-07220060 in participants diagnosed with mBC. Part 2B and Part 2C are expansion for combination therapy of PF-07220060 with letrozole and fulvestrant, respectively. Part 2D is the expansion cohort for combination therapy of PF-07220060 with enzalutamide. Part 2E is an expansion cohort to evaluate PF-07220060 Monotherapy versus PF-07220060 plus fulvestrant combination therapy. The China monotherapy cohort will evaluate safety, tolerability and PK of PF-07220060 administered as single agent in Chinese participants. The Japan monotherapy cohort will evaluate safety, tolerability and PK of PF-07220060 administered as a single agent in Japanese participants. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/02/2025

Locations: Ellison Institute, Los Angeles, California +37 locations

Ellison Institute, Los Angeles, California

Smilow Cancer Hospital at Yale - New Haven, New Haven, Connecticut

Yale-New Haven Hospital-Yale Cancer Center, New Haven, Connecticut

Smilow Cancer Hospital Phase 1 Unit, New Haven, Connecticut

Brigham & Women's Hospital, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

Dana Farber Cancer Institute- Chestnut Hill, Newton, Massachusetts

START Midwest, Grand Rapids, Michigan

Sarah Cannon Research Institute - Pharmacy, Nashville, Tennessee

SCRI Oncology Partners, Nashville, Tennessee

The University of Texas MD Anderson Cancer Center, Houston, Texas

Hospital Británico de Buenos Aires, Ciudad autónoma de Buenos Aires, Buenos Aires

Fundación Cenit Para La Investigación En Neurociencias, Caba, Ciudad Autã³noma DE Buenos Aires

Fundación Respirar, Buenos Aires, Not set

Clínica Universitaria Reina Fabiola, Córdoba, Not set

Fundación CORI para la Investigación y Prevención del Cáncer, La Rioja, Not set

Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing

Henan Cancer Hospital, Zhengzhou, Henan

Hubei Cancer Hospital, Wuhan, Hubei

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang

Fakultni nemocnice Olomouc, Olomouc, Not set

Vseobecna fakultni nemocnice v Praze, Praha 2, Not set

National Cancer Center Hospital East, Kashiwa, Chiba

INCAN, Cdmx, Distrito Federal

Hospital MAC Periferico Sur, Ciudad de Mexico, Distrito Federal

COI Centro Oncologico Internacional S.A.P.I. de C.V., Mexico City, Distrito Federal

Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Nuevo LEÓN

Hospital Reforma, Oaxaca de Juárez, Oaxaca

Oaxaca Site Management Organization, Oaxaca, Not set

Onkologicky ustav sv. Alzbety, s.r.o., Interna klinika VSZaSP a OUSA, Bratislava, Not set

Narodny onkologicky ustav, Bratislava, Not set

Fakultna nemocnica s poliklinikou Nove Zamky, Nove Zamky, Not set

POKO Poprad, s.r.o., Poprad, Not set

Cancer Research UK Edinburgh Centre, Edinburgh, Edinburgh, CITY OF

St Bartholomew's Hospital, London, London, CITY OF

Sarah Cannon Research Institute UK, London, Not set

The Christie Hospital NHS Foundation Trust, Manchester, Not set

Conditions: Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung

Learn More ›

EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma

NCT05619913

Recruiting

The EPOCH study population is patients with tubo-ovarian carcinosarcoma or uterine carcinosarcoma with evidence of recurrence or progression. The study aims to determine the activity of eribulin as a single agent and the combination of eribulin and pembrolizumab as measured by clinical benefit rate (CBR) at 12 weeks. Additionally, the study aims to establish whether high mobility group A2 (HMGA2) protein expression is a good functional biomarker to predict response to eribulin and pembrolizuma... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/02/2025

Locations: Prince of Wales Hospital, Randwick, New South Wales +5 locations

Conditions: Ovarian Carcinosarcoma, Uterine Carcinosarcoma

Learn More ›

EUthyroid2: the Next Step Towards the Elimination of Iodine Deficiency and Preventable Iodine-related Disorders in Europe

NCT06769009

Recruiting

In EUthyroid2 intervention measures are to be developed, implemented in ambulatory care settings and evaluated to effectively raise awareness for the risks of iodine deficiency among young women (18-24 years) in three European countries (Norway, Poland, UK) as well as Bangladesh and Pakistan. A cluster-randomized controlled trial with three points of measurements will be applied in each participating country. The intervention will be adapted to the different contextual characteristics of the imp... Read More

Gender:

FEMALE

Ages:

Between 18 years and 24 years

Trial Updated:

02/01/2025

Locations: Bangladesh University of Health, Dhaka, Not set +5 locations

Conditions: Iodine Deficiency

Learn More ›